In a similar vein, Clark et al. (2018) suggested a growth area for research into the treatment of neurodegenerative disease (e.g., post-stroke syndrome, traumatic brain injury (TBI), AD), could be to reduce chronically elevated levels of Tumor Necrosis Factor (TNF), and other cytokines—elevated levels of which, in turn, generate Aβ [28] . The gene discussed is TNF; the disease is brain injury.